5/12 Taiwan Life Sciences Weekly Newsletter
2025-05-12 |
| Taiwan Life Sciences Weekly |
| Intelligene debuts on the Taipei Exchange, aiming for global market with RNA-based new drug platform 8 May, 2025 Intelligene (TW: 7832), Taiwan's first RNA nucleic acid drug research and development company to list on the Taipei Exchange, set a reference price of NT$4 per share. Today, the stock opened at NT$4.8 and surged to over NT$14 during intraday trading, more than doubling in value. According to the company, in the short term Intelligene is focusing on the development of two products, IG-001 for COVID-19 and IG-002 for the flu. The company plans to advance Phase I clinical trials for these products in the second half of this year and the first half of next year. In the medium to long term, the company aims to establish an RNA nucleic acid drug research platform, with a focus on obtaining FDA platform technology designation. This certification will significantly accelerate the development of new product lines in the future. More... (in Chinese) |
| TAHO Pharmaceuticals' oral film new drug hits key trial milestone 8 May, 2025 TAHO Pharmaceuticals (TW: 6467) announced that its globally first-of-its-kind antithrombotic oral film new drug, TAH3311, has successfully completed the final report of its US pivotal study. The trial results met the primary endpoints. TAHO plans to submit new drug applications (NDAs) to both the US and European markets by the third quarter of this year, aiming to challenge the position of Apixaban--the world's best-selling small-molecule drug--and tap into a market opportunity worth over US$20 billion annually. More... (in Chinese) |
| Medeon Biodesign's prostate medical device clinical trial successfully unblinded 8 May, 2025 Medeon Biodesign's (TW: 6499) minimally invasive treatment device Urocross for benign prostatic hyperplasia (BPH) has completed its Expander-2 pivotal clinical trial conducted in the United States and Canada. Enrollment was completed in December last year, and on May 7 the company announced preliminary results showing significant efficacy after six months of treatment, marking a successful unblinding. More... (in Chinese) |
| Lotus Pharmaceuticals signs licensing agreement with Supernus, secures Asia-Pacific rights for ADHD drug 8 May, 2025 Lotus Pharmaceuticals (TW: 1795) announced that it has signed an exclusive licensing agreement with US-based Supernus Pharmaceuticals to obtain the marketing rights for Qelbree (viloxazine extended-release capsules), a treatment for Attention Deficit Hyperactivity Disorder (ADHD). The agreement covers South Korea, Taiwan, Hong Kong SAR, Indonesia, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam. More... (in Chinese) |
| EverFortune.ai's smart healthcare robot aims for certification by end of year 7 May, 2025 EverFortune.ai (TW: 6841) announced that the company in partnership with Phison Electronics has formed a joint venture--Changlian Technology--to develop a medical care robot. They aim to obtain TFDA approval by the end of 2025, with hopes for mass production, though no specific timeline has been set. EverFortune.ai currently offers three main product categories: medical big data, cloud biomedical platforms, and medical AI software. The company has over 50 global clients, including healthcare institutions and distributors. More... (in Chinese) |
| Formosa Pharmaceuticals and Almac Discovery Announce Licensing Agreement for ALM-401, a First-in-Class Bispecific ADC targeting EGFR/ROR1 for the Treatment of Solid Tumors Press release 6 May, 2025 Taiwan-based Formosa Pharmaceuticals (TW: 6838) announced that the company has entered into an exclusive licensing agreement with Almac Discovery, a Northern Ireland-based research driven drug discovery company, for exclusive rights to the commercialization of ALM-401, a first-in-class, bispecific antibody drug conjugate (ADC) for the treatment of solid tumors characterized by the dual expression of EGFR and ROR1. Almac Discovery, focuses on protein homeostasis and next-generation antibody drug conjugates. Their portfolio of preclinical and clinical stage drug candidates comprises both small and large molecule modalities, and benefits from collaboration and licensing partnerships with global R&D-focused biotech and pharmaceutical organizations. The licensing agreement includes upfront payment and development milestones, with additional considerations through approval and post-commercialization. More... |
| TSH Biopharm partners with AcadeMab to obtain Taiwan market rights for rare CNS disease drug 6 May, 2025 TSH Biopharm (TW: 8432) announced that it has entered into a strategic partnership with AcadeMab Bio to obtain the licensing rights for ZTALMY, a treatment for the rare neurodevelopmental disorder CDKL5 Deficiency Disorder (CDD), in the Taiwan market. This move expands TSH Biopharm's portfolio in the field of central nervous system (CNS) diseases and marks its entry into the rare disease treatment market. CDD typically manifests in infancy, leading to severe epileptic seizures and developmental delays. The World Health Organization (WHO) classified CDD as a rare disease in 2020. However, CDD has not yet been officially recognized as a rare disease in Taiwan. Current antiepileptic drugs on the market offer limited efficacy in treating CDD. More... (in Chinese) |
| MegaPro Bio's nanoparticle technology patented 6 May, 2025 MegaPro Bio (TW: 6827) announced that its independently developed nanoparticle technology, Iron Oxide Nanoparticles Injection (IOP Injection), has officially received a physical copy of its US composition patent certificate. To date, the platform has secured composition patents in the United States, Japan, Europe, Australia, Taiwan, and China, protecting related products under this technology until 2038. The company has developed two key applications from this platform: MPB-1523, an MRI contrast agent for detecting hepatocellular carcinoma (HCC) and MPB-1514, an injectable iron supplement for treating iron-deficiency anemia. More... (in Chinese) |
| PhytoHealth's new pain medication enters Germany, enters collaboration with Aristo Pharma 5 May, 2025 PhytoHealth (TW: 4108) has signed a letter of intent with German pharmaceutical company Aristo Pharma. The two parties will collaborate on the registration of PhytoHealth’s new drug PhytoPain in Germany, paving the way for sales in both Germany and the broader European market. The cooperation will also include licensing fees, laying a foundation for PhytoHealth's entry into Europe. More... (in Chinese) |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Contact: Daisy Tsai Tel: +886 2 27836028 ext 14 FAX : +886 2 27836027 Mobile: +886 933-139647 | Line ID : daisy222 Email: daisy@taiwanbio.org.tw BIO Asia-Taiwan 2025 (23-27 July, 2025) ========================================= Taiwan Bio Industry Organization (TBIO) Room C229, Bldg. C, No.99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |